Dexpramipexole dihydrochloride Catalog No.:M9926-2 7Sodium Channel inhibitor1 demonstrated concentration-dependent

7Sodium Channel inhibitor1 demonstrated concentration-dependent efficacy in preclinical behavioral pain models

2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine

AG14361 markedly enhances NSC 362856 activity against LoVo xenografts and delays tumor growth when combined with NSC 362856

Ginsenoside Rb2 enhances the anti-inflammatory effect of ω-3 fatty acid in LPS-stimulated RAW264

including T315I

Dexpramipexole dihydrochloride Catalog No.:M9926-2 7Sodium Channel inhibitor1 demonstrated concentration-dependentDexpramipexole, also known as KNS 760704 and (R) Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well